TORONTO, ON / ACCESSWIRE / January 6, 2021 / Fibrocor Therapeutics Inc. (“Fibrocor” or “the Company”), a privately held developer of de novo therapeutics to treat fibrotic diseases, announced today the appointment of industry veteran Joseph Walewicz as Chief Financial Officer.
Joseph (Joe) Walewicz has over 25 years of experience in finance, capital markets and business development. Prior to joining Fibrocor, Joe was Executive Vice President of Business and Corporate Development at Clementia Pharmaceuticals, joining the executive team prior to its successful NASDAQ IPO in 2017, and continuing through to IPSEN’s US$1 billion acquisition of Clementia in 2019. Previously, Joe was an executive at two other successful publicly traded biopharma companies, and a ranked investment analyst at major North American investment banks.
“We are very pleased to welcome Joe to the Fibrocor executive team, and we expect that his experience in finance, capital markets and business development will be extremely valuable as we grow and expand our business”, stated Mark Steedman, Chief Executive Officer, Fibrocor.
“I am thrilled to join the team at this critical junction, as Fibrocor’s key discovery programs progress towards clinical development”, commented Joe Walewicz. “I look forward to helping Fibrocor continue to build a world class development team that will advance its clinical programs, while also expanding and accelerating our innovative discovery efforts in fibrotic diseases.”
ABOUT FIBROCOR THERAPEUTICS INC.
Fibrocor is a privately held, tissue specific, drug discovery company. It is pioneering the use of tissue specific therapeutics in the field of precision medicine and in particular, Fibrosis. The company has partnered with leading research institutes in Toronto, Canada, to aggregate and interrogate diseased fibrotic tissue samples in a number of organ systems to understand the genesis of the disease and its manifestations in fast progressing populations. For more information visit fibrocortherapeutics.com.
Julie A. Fotheringham
Partner, HAGEMAN Communications
SOURCE: Fibrocor Therapeutics Inc.
View source version on accesswire.com: